NEWS

Back
Title

Microbiome Emerges as a Biomarker

Posted by aidot(ip:)

Date 2023-03-14

View 151

Rate 0점  

Recommend Recommend this

Message


[View Original Text]



<Anchor> Time for IPO freeboard.

Recently, research is drawing attention that microbiome diagnoses and predicts diseases by combining with artificial intelligence beyond the development of treatments.

Let's get to know this issue with reporter Jae-joon Yang.

There are also microbiome-related listed companies such as Genome & Company and CJ Bioscience, and I heard that research on biomarkers has been actively conducted recently 

right?


<Reporter> Last July 2021, CJ CheilJedang once drew attention when it bought a 44% stake in CJ Bioscience (Chunlab), a microbiome company listed on the KOSDAQ, for 98.3 billion won.


Microbiome is a generic term for various microorganisms such as individual-level bacteria and viruses that live in our body.


Microbiome has previously been used to make health functional foods and cosmetics, but it has attracted attention since the development of treatments began several years ago.


In December last year, the U.S. Food and Drug Administration (FDA) approved Swiss Fering Pharmaceutical's "REBYOTA" and succeeded in developing a microbiome treatment for the 

first time. (Recurring Clostridium difficile Infection Permission)


As microbiome is combined with the research and development of treatments, it is now evolving into a biomarker.


Biomarkers refer to indicators that can detect changes in the body using proteins, DNA, RNA (ribonucleic acid), and metabolites.


Microbiome is the basis for judging the diagnosis, stage, and prognosis of diseases beyond the development of treatments.


<Anchor> It is interpreted that research and development on biomarkers is expanding based on microbiome.

What companies are developing biomarkers based on microbiome in Korea?


<Reporter> Biomarkers based on microbiome are actively researching and developing not only small and medium-sized biotech but also large pharmaceutical companies through partnerships and M&As.


Like CJ CheilJedang, Shinsegae made a strategic investment in Go Bio Lab, Celltrion recently signed a joint research and development contract with Rescure Bioscience and 

Parkinson's disease treatment following Go Bio Lab last year, and Chong Kun Dang Bio also started developing microbiome treatments with Yonsei University Medical Center.


Yuhan Corporation acquired A2GEN in September last year to develop microbiome treatments, and LG Chem is developing microbiome anticancer drugs with Genome & Company.


In addition, GI Biome, a subsidiary of GI Innovation, received approval from the Ministry of Food and Drug Safety last month for a phase 1 clinical trial plan (IND) for new colorectal 

cancer and rectal cancer candidates (GB-104) to develop biomarker analysis.


<Anchor> There is also an atmosphere in which biomarker research and development on microbiome is expanding to the digital health field in combination with artificial intelligence 

technology, so could you tell me about this?


< Reporter> As you just said, research partnerships using artificial intelligence are also actively developing.


Hancom Care Link plans to develop health examination services by utilizing bio big data company 3Vix and microbiome-based biomarker analysis technology.


Terrazen Genome Care, an artificial intelligence-based genetic analysis company, recently signed a business agreement with Ingenome, a microbiome analysis company, to build 

microbiome analysis services.


In addition, DX & VX (DxVx) is participating in overseas research on microbiome biomarkers to develop diabetes and obesity treatments and digital prevention solutions with Corey 

Group.


Also, AIDOT, a medical artificial intelligence company, is developing a microbiome-based liver disease treatment AI solution.


The principle is to specify alcoholic liver disease by incorporating next-generation sequencing (NGS) into the results of microbiome research and apply it to AI algorithms.


Let's listen to Jae-hoon Jeong, CEO of AIDOT for details.


[Interview: Jae-hoon Jeong, CEO of AIDOT / "We found biomarkers through a species that we've been developing for about two years. This time, we are working on additional 

advancements through additional collaboration with famous medical foundations in Korea. So we plan to receive a lot of help from the Gangwon Special District on regulations for 

commercialization to prepare commercialization in the second half of this year."]


<Anchor> We are talking about biomarkers of microbiome, what are the benefits or benefits of biomarkers using artificial intelligence from the perspective of actual patients?


<Reporter> Usually, in order to detect colon cancer or liver cancer, examination methods such as endoscopy, ultrasound, or MRI are used. In this case, the patient may visit the hospital for an examination, but the sensitivity may be low, and some tissue tests may be required to increase accuracy, which could be a burden on the patient.


If artificial intelligence is used, it can increase the accuracy of the test with the judgment of the medical staff, and it is also cheaper than general tests.


Let's listen to Jae-hoon Jeong, CEO of AIDOT for details.


[Interview: Jae-hoon Jeong, CEO of AIDOT /"We simply find biomarkers through feces of harmful substances in the human body, and once we did a liver test, we approached them in a way that consumers and patients could easily access. We are now considering the cost of 1/2 of the cost of liver examination in MRI in the existing market. We can also make any 

contribution in terms of cost, but not only that, we're now working to improve MRI-equivalent screening (results) in terms of accuracy."]



Korea Economic TV / Reporter Jae-joon Yang  / 10th. Mar. 2023


Attachment news.png

Password
Edit

Please enter password to remove or edit this post.

Comments

There are no comments to display.

Edit Comment

Name

Password

Message

/ byte

Edit Cancel
Password :
OK Cancel
Add Comment

Name

Password

Combination in 10-16 characters containing at least two of the followings: upper and lower case letters/numbers/special letters

Message

/ byte

Rate

Please type without any spaces.

Comments can be added by Member only.

WORLD SHIPPING

PLEASE SELECT THE DESTINATION COUNTRY AND LANGUAGE :

GO
닫기